Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review

被引:57
作者
Dimitrakopoulou-Strauss, Antonia [1 ]
Ronellenfitsch, Ulrich [2 ]
Cheng, Caixia [1 ]
Pan, Leyun [1 ]
Sachpekidis, Christos [1 ]
Hohenberger, Peter [2 ]
Henzler, Thomas [3 ]
机构
[1] German Canc Res Ctr, Clin Cooperat Unit Nucl Med, Neuenheimer Feld 280, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Div Surg Oncol & Thorac Surg,Dept Surg, Mannheim, Germany
[3] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Inst Clin Radiol & Nucl Med, Mannheim, Germany
关键词
Molecular imaging; PET; GIST; Oncology; Therapy monitoring; Personalized medicine; POSITRON-EMISSION-TOMOGRAPHY; DUAL-ENERGY CT; IMATINIB MESYLATE TREATMENT; SOFT-TISSUE SARCOMA; COMPUTED-TOMOGRAPHY; EARLY PREDICTION; PHASE-II; EVALUATION CRITERIA; CHOI CRITERIA; FOLLOW-UP;
D O I
10.1007/s40336-017-0229-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose Improvement of the therapeutic approaches in gastrointestinal stromal tumors (GIST) by the introduction of targeted therapies requires appropriate diagnostic tools, which allow sufficient assessment of therapeutic response, including differentiation of true progression from pseudoprogression due to myxoid degeneration or intratumoral hemorrhage. In this literature review the impact and limitations of different imaging modalities used in GIST therapy monitoring are discussed. Methods PubMed and Cochrane library search were performed using appropriate keywords. Overall, 39 original papers fulfilled the defined criteria and were included in this systematic review. Results Morphological imaging modalities like computed tomography (CT) are primarily used for both diagnosis and therapy monitoring. However, therapy with tyrosine kinase inhibitors and other targeted therapies in GIST may lead only to a minor tumor volume reduction even in cases of response. Therefore, the use of Response Evaluation Criteria in Solid Tumors (RECIST) has limitations. To overcome those limitations, modified response criteria have been introduced for the CT-based therapy assessment, like the Choi criteria as well as criteria based on dual energy CT studies. Functional imaging techniques, mostly based on FDG PET-CT are in use, in particular for the assessment of early treatment response. Conclusions The impact and the limitations of PET-based therapy monitoring, as well as its comparison with CT, MRI and survival data are discussed in this review. CT is still the standard method for the evaluation of therapy response despite its several limitations. FDG PET-CT is helpful for the assessment of early therapy response; however, more prospective data are needed to define its role as well as the appropriate time intervals for therapy monitoring. A multiparametric evaluation based on changes in both morphological and functional data has to be assessed in further prospective studies.
引用
收藏
页码:183 / 197
页数:15
相关论文
共 57 条
  • [1] Antoch G, 2004, J NUCL MED, V45, P357
  • [2] Contrast-Enhanced Dual-Energy CT of Gastrointestinal Stromal Tumors Is Iodine-Related Attenuation a Potential Indicator of Tumor Response?
    Apfaltrer, Paul
    Meyer, Mathias
    Meier, Caroline
    Henzler, Thomas
    Barraza, John M., Jr.
    Dinter, Dietmar J.
    Hohenberger, Peter
    Schoepf, U. Joseph
    Schoenberg, Stefan O.
    Fink, Christian
    [J]. INVESTIGATIVE RADIOLOGY, 2012, 47 (01) : 65 - 70
  • [3] Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
    Bauer, S.
    Hilger, R. A.
    Muehlenberg, T.
    Grabellus, F.
    Nagarajah, J.
    Hoiczyk, M.
    Reichardt, A.
    Ahrens, M.
    Reichardt, P.
    Grunewald, S.
    Scheulen, M. E.
    Pustowka, A.
    Bock, E.
    Schuler, M.
    Pink, D.
    [J]. BRITISH JOURNAL OF CANCER, 2014, 110 (05) : 1155 - 1162
  • [4] Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
    Benjamin, Robert S.
    Schoffski, Patrick
    Hartmann, Joerg Thomas
    Van Oosterom, Allan
    Binh Nguyen Bui
    Duyster, Justus
    Schuetze, Scott
    Blay, Jean-Yves
    Reichardt, Peter
    Rosen, Lee S.
    Skubitz, Keith
    McCoy, Sheryl
    Sun, Yu-Nien
    Stepan, Daniel E.
    Baker, Laurence
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (01) : 69 - 77
  • [5] Chacón M, 2015, FUTURE ONCOL, V11, P953, DOI [10.2217/FON.14.292, 10.2217/fon.14.292]
  • [6] CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: A quantitative analysis correlated with FDG PET findings
    Choi, H
    Charnsangavej, C
    Faria, SD
    Tamm, EP
    Benjamin, RS
    Johnson, MM
    Macapinlac, HA
    Podoloff, DA
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2004, 183 (06) : 1619 - 1628
  • [7] Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
    Choi, Haesun
    Charnsangavej, Chuslip
    Faria, Silvana C.
    Macapinlac, Homer A.
    Burgess, Michael A.
    Patel, Shreyaskumar R.
    Chen, Lei L.
    Podoloff, Donald A.
    Benjamin, Robert S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1753 - 1759
  • [8] Biology of gastrointestinal stromal tumors
    Corless, CL
    Fletcher, JA
    Heinrich, MC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (18) : 3813 - 3825
  • [9] Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors
    De Giorgi, U
    Aliberti, C
    Benea, G
    Conti, M
    Marangolo, M
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (17) : 6171 - 6176
  • [10] De Giorgi U, 2005, MOL CANCER THER, V4, P495